Shares of MEDNAX Inc (NYSE:MD) have been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $26.56.
A number of research analysts recently weighed in on MD shares. ValuEngine raised MEDNAX from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. BMO Capital Markets reduced their price target on MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a research note on Monday, August 5th. Mizuho set a $25.00 price target on MEDNAX and gave the company a “hold” rating in a research note on Friday, November 1st. Bank of America downgraded MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price target for the company. in a research note on Friday, September 6th. Finally, Zacks Investment Research upgraded MEDNAX from a “sell” rating to a “hold” rating and set a $23.00 price target for the company in a research note on Monday, October 14th.
Shares of MD stock traded up $0.59 during trading on Thursday, reaching $26.69. 823,858 shares of the company’s stock were exchanged, compared to its average volume of 1,417,081. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $2.20 billion, a PE ratio of 7.60, a PEG ratio of 1.02 and a beta of 0.70. MEDNAX has a twelve month low of $19.93 and a twelve month high of $40.81. The firm’s fifty day moving average price is $23.35 and its 200-day moving average price is $24.15.
MEDNAX (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.08. The business had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. MEDNAX had a positive return on equity of 10.38% and a negative net margin of 40.86%. The firm’s revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. As a group, analysts anticipate that MEDNAX will post 3.02 EPS for the current fiscal year.
In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the sale, the director now directly owns 10,821 shares in the company, valued at approximately $247,584.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Denali Advisors LLC purchased a new stake in MEDNAX during the second quarter valued at about $507,000. WINTON GROUP Ltd increased its holdings in shares of MEDNAX by 79.6% in the 2nd quarter. WINTON GROUP Ltd now owns 802,412 shares of the company’s stock valued at $20,245,000 after purchasing an additional 355,681 shares during the period. First Citizens Bank & Trust Co. acquired a new position in shares of MEDNAX in the 2nd quarter valued at about $230,000. 6 Meridian increased its holdings in shares of MEDNAX by 4.5% in the 2nd quarter. 6 Meridian now owns 13,850 shares of the company’s stock valued at $349,000 after purchasing an additional 594 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its holdings in shares of MEDNAX by 1.4% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 37,568 shares of the company’s stock valued at $948,000 after purchasing an additional 503 shares during the period. Hedge funds and other institutional investors own 92.27% of the company’s stock.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Featured Story: What causes a stock to be most active?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.